---
title: "Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295525767.md"
description: "Phio Pharmaceuticals received a U.S. Notice of Allowance for a patent covering PH-894, an INTASYL siRNA targeting BRD4. This approval strengthens intellectual property protection for the compound's chemical structure and therapeutic applications in proliferative and infectious diseases. The company now holds 54 issued patents across its INTASYL portfolio."
datetime: "2026-08-11T11:04:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295525767.md)
  - [en](https://longbridge.com/en/news/295525767.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295525767.md)
---

# Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894

-   Phio Pharmaceuticals received a U.S. Notice of Allowance for a patent covering PH-894, an INTASYL siRNA designed to selectively silence BRD4. \* The company framed the patent as strengthening IP protection for PH-894’s chemical structure, genetic sequencing, and potential uses in proliferative and infectious diseases. \* Phio reported its patent portfolio totals 54 issued patents across INTASYL chemistry, gene targets, and therapeutic applications. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608110700NEWSFILECNPR\_\_\_\_20260811\_309064\_1) on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [PHIO.US](https://longbridge.com/en/quote/PHIO.US.md)

## Related News & Research

- [Silence Therapeutics Announces Major ADS Public Offering](https://longbridge.com/en/news/295715727.md)
- [CSPC Pharmaceutical receives USD 30 million upfront payment from AstraZeneca under siRNA pact](https://longbridge.com/en/news/295663654.md)
- [PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal](https://longbridge.com/en/news/296027001.md)
- [CHAR Tech Reports Elimination of PFAS in Biochar from HTP Testing | CTRNF Stock News](https://longbridge.com/en/news/296101954.md)
- [VibroSense wins Japan patent for chemotherapy-induced neuropathy biomarker](https://longbridge.com/en/news/295890805.md)